Business
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis
Landmark Study Published in the New England Journal of Medicine Shows Important Benefits of Eprodisate (KIACTA(TM)) Treatment for Patients with Amyloid A (AA) Amyloidosis.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\nECUBLENS, SWITZERLAND, June 7 /CNW Telbec/ - Neurochem (International)\nLimited (Neurochem), a wholly-owned subsidiary of Neurochem Inc. (NASDAQ:\nNRMX; TSX: NRM), announces that the New England Journal of Medicine (NEJM)\npublished the results of the "Eprodisate For AA Amyloidosis Trial" (EFAAT),\nrecognized as a landmark clinical trial in the search for a treatment of AA\namyloidosis. The results of the Phase II/III clinical trial for eprodisate\n(KIACTA(TM)) demonstrate that this product candidate offers important clinical\nbenefits to patients by reducing the progression of AA amyloidosis-associated\nrenal disease. The results from the EFAAT have been submitted to the U.S. Food\nand Drug Administration, the European Medicines Agency and Swissmedic in\nsupport of applications for marketing approval of eprodisate (KIACTA(TM)) for\nthe treatment of AA amyloidosis, a disease which remains today without a\nspecific treatment.\n\n\nThe print issue of the publication will be available in the June 7, 2007\nissue of the NEJM. The article entitled "Eprodisate for the Treatment of Renal\nDisease in AA Amyloidosis" is accessible online, and can be found at\nwww.nejm.org under the "Current Issue" section of the Web site.\n\n\n"These results show clinically important benefits for patients suffering\nfrom this disabling and potentially fatal disease," said Dr. Laura Dember,\nnephrologist and Associate Professor of Medicine, Boston University School of\nMedicine, and the lead author of the New England Journal of Medicine article\nreporting the results of the Phase II/III clinical trial for eprodisate\n(KIACTA(TM)). "Our treatment approach, up to this point, has been limited to\ncontrolling the inflammatory condition that underlies the development of AA\namyloidosis. However, for many patients such efforts are unsuccessful and\namyloid formation continues. KIACTA(TM) is the first product candidate\ndesigned to target amyloid formation and represents a truly novel strategy for\ntreating nephropathy associated with AA amyloidosis," she concluded.\n\n\nFindings about eprodisate (KIACTA(TM)) reported in the article include:\n\n- At the end of the 24-month period, the disease had worsened in 24 of\n 89 patients assigned to eprodisate (KIACTA(TM)) (27%), and 38 of\n 94 patients given placeb...